|
US20030225150A1
(en)
*
|
1997-04-21 |
2003-12-04 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
|
|
US20040072889A1
(en)
*
|
1997-04-21 |
2004-04-15 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
|
|
PA8469601A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Procedimiento para alquilar sulfonamidas impedidas estericamente
|
|
PA8469301A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Procedimientos para la preparacion de acidos hidroxamicos.
|
|
GT199900044A
(es)
*
|
1998-04-10 |
2000-09-14 |
|
Procedimientos para preparar haluros de fenoxifenilsulfonilo.
|
|
US6858598B1
(en)
|
1998-12-23 |
2005-02-22 |
G. D. Searle & Co. |
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
|
US20040122011A1
(en)
*
|
1998-12-23 |
2004-06-24 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
|
|
US20030203956A1
(en)
*
|
1998-12-23 |
2003-10-30 |
Masterrer Jaime L. |
Method of using a cyclooxygenase-2 inhibitor and one or more ornithine decarboxylase inhibitors as a combination therapy in the treatment of neoplasia
|
|
US20030119895A1
(en)
*
|
1998-12-23 |
2003-06-26 |
Pharmacia Corporation |
Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
|
|
US20030013739A1
(en)
*
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
|
US20020103141A1
(en)
*
|
1998-12-23 |
2002-08-01 |
Mckearn John P. |
Antiangiogenic combination therapy for the treatment of cancer
|
|
US20040053900A1
(en)
*
|
1998-12-23 |
2004-03-18 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
|
|
US6833373B1
(en)
|
1998-12-23 |
2004-12-21 |
G.D. Searle & Co. |
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
|
ES2344592T3
(es)
|
2001-01-05 |
2010-09-01 |
Pfizer Inc. |
Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
|
|
WO2003000194A2
(en)
|
2001-06-21 |
2003-01-03 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
WO2003045433A1
(fr)
*
|
2001-11-29 |
2003-06-05 |
Nippon Organon K.K. |
Remedes contre l'insuffisance cardiaque
|
|
PE20030701A1
(es)
|
2001-12-20 |
2003-08-21 |
Schering Corp |
Compuestos para el tratamiento de trastornos inflamatorios
|
|
AU2003206068A1
(en)
|
2002-03-01 |
2003-09-16 |
Pfizer Inc. |
Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
|
|
TWI350285B
(en)
|
2002-03-13 |
2011-10-11 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
|
EA008501B1
(ru)
|
2002-12-19 |
2007-06-29 |
Пфайзер Инк. |
2-(1н-индазол-6-иламино)бензамидные соединения как ингибиторы протеинкиназ, полезные для лечения офтальмологических заболеваний
|
|
CN103265477B
(zh)
|
2003-02-26 |
2017-01-11 |
苏根公司 |
作为蛋白激酶抑制剂的氨基杂芳基化合物
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
BRPI0413876A
(pt)
|
2003-08-29 |
2006-10-24 |
Pfizer |
tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
|
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
ES2369835T3
(es)
|
2003-11-19 |
2011-12-07 |
Array Biopharma, Inc. |
Inhibidores bicíclicos de mek y métodos de síntesis de los mismos.
|
|
ATE473967T1
(de)
*
|
2003-11-26 |
2010-07-15 |
Pfizer Prod Inc |
Aminopyrazolderivate als gsk-3-inhibitoren
|
|
EP1802341A1
(de)
|
2004-07-16 |
2007-07-04 |
Pfizer Products Inc. |
Kombinationsbehandlung für nicht-hämatologische bösartige erkrankungen mit einem anti-igf-1r-antikörper
|
|
KR100859891B1
(ko)
|
2004-08-26 |
2008-09-23 |
화이자 인코포레이티드 |
단백질 키나제 억제제로서 거울상이성질체적으로 순수한아미노헤테로아릴 화합물
|
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
|
US7429667B2
(en)
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
|
EP2361905B1
(de)
|
2005-05-18 |
2013-03-06 |
Array Biopharma Inc. |
Heterocyclische MEK Inhibitoren und ihre Verwendung
|
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
|
CA2623125A1
(en)
|
2005-09-20 |
2007-03-29 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
TWI405756B
(zh)
|
2005-12-21 |
2013-08-21 |
Array Biopharma Inc |
新穎硫酸氫鹽
|
|
US7842836B2
(en)
|
2006-04-11 |
2010-11-30 |
Ardea Biosciences |
N-aryl-N'alkyl sulfamides as MEK inhibitors
|
|
EA016674B1
(ru)
|
2006-04-18 |
2012-06-29 |
Ардеа Байосайенсиз, Инк. |
Пиридон сульфонамиды и пиридон сульфамиды в качестве ингибиторов mek
|
|
EP2121626A1
(de)
|
2006-12-15 |
2009-11-25 |
Pfizer Products Inc. |
Benzimidazolderivate
|
|
JP5491199B2
(ja)
|
2007-01-19 |
2014-05-14 |
アルデア バイオサイエンシズ，インコーポレイティド |
Ｍｅｋのインヒビター
|
|
JP4782239B2
(ja)
|
2007-04-18 |
2011-09-28 |
ファイザー・プロダクツ・インク |
異常細胞増殖治療のためのスルホニルアミド誘導体
|
|
US8530463B2
(en)
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
|
JP5479337B2
(ja)
|
2007-07-30 |
2014-04-23 |
アルディア バイオサイエンス，インク． |
Ｍｅｋ阻害剤およびｒａｆキナーゼ阻害剤の組み合わせ、ならびにその使用
|
|
AR069803A1
(es)
|
2007-12-19 |
2010-02-17 |
Genentech Inc |
5- anilinoimiazopiridinas y metodos de uso
|
|
ES2387707T3
(es)
|
2007-12-21 |
2012-09-28 |
Genentech, Inc. |
Azaindolizinas y procedimientos de uso
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
CN104926815B
(zh)
|
2008-01-04 |
2017-11-03 |
英特利凯恩有限责任公司 |
某些化学实体、组合物和方法
|
|
JP5547099B2
(ja)
|
2008-03-14 |
2014-07-09 |
インテリカイン， エルエルシー |
キナーゼ阻害剤および使用方法
|
|
WO2009121039A2
(en)
|
2008-03-28 |
2009-10-01 |
Hale Biopharma Ventures, Llc |
Administration of benzodiazepine compositions
|
|
WO2010006086A2
(en)
|
2008-07-08 |
2010-01-14 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
|
CA2737597C
(en)
|
2008-10-16 |
2017-03-14 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
|
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
|
PL2385938T3
(pl)
|
2009-01-12 |
2015-07-31 |
Pfizer Ltd |
Pochodne sulfonamidu
|
|
EP3360879A1
(de)
|
2009-02-05 |
2018-08-15 |
ImmunoGen, Inc. |
Benzodiazepinderivate als cytotoxischen agenten
|
|
SG172857A1
(en)
|
2009-02-09 |
2011-08-29 |
Supergen Inc |
Pyrrolopyrimidinyl axl kinase inhibitors
|
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
|
US20100222381A1
(en)
|
2009-02-27 |
2010-09-02 |
Hariprasad Vankayalapati |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
EP2401614A1
(de)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
|
|
WO2010108652A1
(en)
|
2009-03-27 |
2010-09-30 |
Ardea Biosciences Inc. |
Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors
|
|
JP5789252B2
(ja)
|
2009-05-07 |
2015-10-07 |
インテリカイン， エルエルシー |
複素環式化合物およびその使用
|
|
JP2013500991A
(ja)
|
2009-07-31 |
2013-01-10 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
ｍＴＯＲ阻害剤および血管新生阻害剤併用療法
|
|
AU2010284254B2
(en)
|
2009-08-17 |
2015-09-17 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
WO2011027249A2
(en)
|
2009-09-01 |
2011-03-10 |
Pfizer Inc. |
Benzimidazole derivatives
|
|
ES2534358T3
(es)
|
2009-10-13 |
2015-04-21 |
Allomek Therapeutics, Llc |
Inhibidores novedosos de MEK útiles en el tratamiento de enfermedades
|
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
|
HRP20171537T1
(hr)
|
2009-11-05 |
2017-12-15 |
Rhizen Pharmaceuticals S.A. |
Novi modulatori benzopiran kinaze
|
|
TW201129384A
(en)
|
2010-02-10 |
2011-09-01 |
Immunogen Inc |
CD20 antibodies and uses thereof
|
|
JP5745283B2
(ja)
|
2010-02-12 |
2015-07-08 |
ファイザー・インク |
８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６Ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンの塩および多形体
|
|
EP2519826A2
(de)
|
2010-03-03 |
2012-11-07 |
OSI Pharmaceuticals, LLC |
Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
|
|
US20110217309A1
(en)
|
2010-03-03 |
2011-09-08 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
EP2571878B1
(de)
|
2010-05-17 |
2018-10-17 |
Incozen Therapeutics Pvt. Ltd. |
Neuartige 3,5-disubstituierte-3h-imidazo[4,5-b]pyridin- und 3,5- disubstituierte -3h-[1,2,3]triazol[4,5-b]pyridin- verbindungen als proteinkinasemodulatoren
|
|
WO2011146882A1
(en)
|
2010-05-21 |
2011-11-24 |
Intellikine, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
|
JP2013538042A
(ja)
|
2010-06-16 |
2013-10-10 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
エンドプラスミンに対する抗体およびその使用
|
|
CA2804173C
(en)
|
2010-07-09 |
2015-01-13 |
Pfizer Limited |
Sulfonamide nav1.7 inhibitors
|
|
EP2630134B9
(de)
|
2010-10-20 |
2018-04-18 |
Pfizer Inc |
Pyridine-2- derivate als modulatoren des smoothened rezeptors
|
|
CN103298474B
(zh)
|
2010-11-10 |
2016-06-29 |
无限药品股份有限公司 |
杂环化合物及其用途
|
|
AR084824A1
(es)
|
2011-01-10 |
2013-06-26 |
Intellikine Inc |
Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
|
|
CA2825894C
(en)
|
2011-02-02 |
2021-11-30 |
Amgen Inc. |
Prognosis of cancer using a circulating biomarker
|
|
RS58620B1
(sr)
|
2011-02-15 |
2019-05-31 |
Immunogen Inc |
Metodi pripremanja konjugata
|
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
|
EP2678016B1
(de)
|
2011-02-23 |
2016-08-10 |
Intellikine, LLC |
Heterocyclische verbindungen und ihre verwendung
|
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
|
DK2699598T3
(en)
|
2011-04-19 |
2019-04-23 |
Pfizer |
COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
|
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
BR112013027774B1
(pt)
|
2011-05-04 |
2020-11-17 |
Rhizen Pharmaceuticals S.A. |
composto e composição farmacêutica
|
|
ES2683902T3
(es)
|
2011-06-14 |
2018-09-28 |
Hale Biopharma Ventures, Llc |
Administración de benzodiacepina
|
|
CA2842190A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2013012915A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
|
PT3409278T
(pt)
|
2011-07-21 |
2020-12-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de proteína cinase heterocíclicos
|
|
CN103998442B
(zh)
|
2011-08-29 |
2016-09-14 |
无限药品股份有限公司 |
杂环化合物及其用途
|
|
ES2575710T3
(es)
|
2011-09-22 |
2016-06-30 |
Pfizer Inc |
Derivados de pirrolopirimidina y purina
|
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
|
US9783613B2
(en)
|
2011-10-04 |
2017-10-10 |
Igem Therapeutics Limited |
IgE anti-HMW-MAA antibody
|
|
KR20140076602A
(ko)
|
2011-11-08 |
2014-06-20 |
화이자 인코포레이티드 |
항-m-csf 항체를 사용한 염증성 장애의 치료 방법
|
|
EP2817004B1
(de)
|
2012-02-22 |
2018-04-11 |
The Regents of The University of Colorado, A Body Corporate |
Bouvardin-derivate und therapeutische verwendung davon
|
|
US9452215B2
(en)
|
2012-02-22 |
2016-09-27 |
The Regents Of The University Of Colorado |
Bourvadin derivatives and therapeutic uses thereof
|
|
MX359888B
(es)
|
2012-03-30 |
2018-10-15 |
Rhizen Pharmaceuticals Sa |
Novedosos compuestos de 3h-imidazo [4,5-b] piridina 3,5-disubstituida y 3h- [1,2,3] triazolo [4,5-b] piridina 3,5-disubstituida como moduladores de c-met proteina cinasas.
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
HUE043552T2
(hu)
|
2012-06-08 |
2019-09-30 |
Sutro Biopharma Inc |
Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
|
|
EP3135690A1
(de)
|
2012-06-26 |
2017-03-01 |
Sutro Biopharma, Inc. |
Modifizierte fc-proteine mit stellenspezifischen nichtnatürlichen aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
|
|
EP2887965A1
(de)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Zytotoxische benzodiazepin-derivate
|
|
BR112015004022B1
(pt)
|
2012-08-31 |
2023-04-25 |
Sutro Biopharma, Inc |
Aminoácidos modificados compreendendo um grupo azido
|
|
DK2909181T3
(da)
|
2012-10-16 |
2017-11-20 |
Tolero Pharmaceuticals Inc |
PKM2-modulatorer og fremgangsmåder til anvendelse deraf
|
|
HRP20181367T4
(hr)
|
2012-11-01 |
2021-11-26 |
Infinity Pharmaceuticals, Inc. |
Liječenje raka korištenjem modulatora izoforme pi3 kinaze
|
|
WO2014134483A2
(en)
|
2013-02-28 |
2014-09-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
|
JP6423804B2
(ja)
|
2013-02-28 |
2018-11-14 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤を含む複合体
|
|
DK2970205T3
(da)
|
2013-03-14 |
2019-07-29 |
Tolero Pharmaceuticals Inc |
JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf
|
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
US20160024051A1
(en)
|
2013-03-15 |
2016-01-28 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
MX364438B
(es)
|
2013-03-15 |
2019-04-26 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
HK1219421A1
(zh)
|
2013-03-15 |
2017-04-07 |
因特利凯有限责任公司 |
激酶抑制剂的组合及其用途
|
|
EP3003309B1
(de)
|
2013-05-30 |
2020-09-09 |
Infinity Pharmaceuticals, Inc. |
Behandlung von krebs mit pi3-kinase-isoformmodulatoren
|
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
KR20160081908A
(ko)
|
2013-10-03 |
2016-07-08 |
쿠라 온콜로지, 인크. |
Erk의 억제제 및 사용 방법
|
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
MX389256B
(es)
|
2013-10-04 |
2025-03-20 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos.
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
EA033689B9
(ru)
|
2013-10-10 |
2020-04-29 |
Араксис Фарма Ллк |
Ингибиторы g12c kras
|
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
|
US20160244452A1
(en)
|
2013-10-21 |
2016-08-25 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
|
CR20160497A
(es)
|
2014-04-30 |
2016-12-20 |
Pfizer |
Derivados de diheterociclo enlazado a cicloalquilo
|
|
SMT201900142T1
(it)
|
2014-06-19 |
2019-05-10 |
Ariad Pharma Inc |
Composti eteroarilici per inibizione di chinasi
|
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
|
EP3473271B1
(de)
|
2014-07-31 |
2022-07-20 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Humane monoklonale antikörper gegen epha4 und deren verwendung
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
|
ES2826443T3
(es)
|
2014-09-25 |
2021-05-18 |
Araxes Pharma Llc |
Inhibidores de proteínas mutantes KRAS G12C
|
|
ES2746839T3
(es)
|
2014-12-18 |
2020-03-09 |
Pfizer |
Derivados de pirimidina y triazina y su uso como inhibidores de AXL
|
|
MX382355B
(es)
|
2015-04-10 |
2025-03-13 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituidos y métodos de uso de los mismos.
|
|
CA2982360A1
(en)
|
2015-04-15 |
2016-10-20 |
Liansheng Li |
Fused-tricyclic inhibitors of kras and methods of use thereof
|
|
RU2717829C2
(ru)
|
2015-04-20 |
2020-03-26 |
Толеро Фармасьютикалз, Инк. |
Прогнозирование ответа на альвоцидиб с помощью анализа профиля митохондрий
|
|
MX382566B
(es)
|
2015-05-01 |
2025-03-13 |
Univ Emory |
Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer
|
|
PT3298021T
(pt)
|
2015-05-18 |
2019-08-05 |
Tolero Pharmaceuticals Inc |
Pró-fármacos de alvocidib possuindo biodisponibilidade aumentada
|
|
TWI703150B
(zh)
|
2015-06-04 |
2020-09-01 |
美商庫拉腫瘤技術股份有限公司 |
用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
|
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
JP7083497B2
(ja)
|
2015-08-03 |
2022-06-13 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
がんの処置のための併用療法
|
|
CN114230571B
(zh)
|
2015-09-14 |
2025-07-08 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
|
EP3356354A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058807A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
JP2018533939A
(ja)
|
2015-10-19 |
2018-11-22 |
アラクセス ファーマ エルエルシー |
Ｒａｓの阻害剤をスクリーニングするための方法
|
|
MX2018005967A
(es)
|
2015-11-16 |
2018-08-29 |
Araxes Pharma Llc |
Compuestos de quinazolina 2-sustituida que comprenden un grupo heterociclico sustituido y metodos de uso de los mismos.
|
|
WO2017096165A1
(en)
|
2015-12-03 |
2017-06-08 |
Agios Pharmaceuticals, Inc. |
Mat2a inhibitors for treating mtap null cancer
|
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
WO2017132617A1
(en)
|
2016-01-27 |
2017-08-03 |
Sutro Biopharma, Inc. |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
|
PH12018501955B1
(en)
|
2016-03-16 |
2024-01-24 |
Kura Oncology Inc |
Bridged bicyclic inhibitors of menin-mll and methods of use
|
|
SI3429591T1
(sl)
|
2016-03-16 |
2023-07-31 |
Kura Oncology, Inc. |
Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe
|
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
US11883381B2
(en)
|
2016-05-12 |
2024-01-30 |
The Regents Of The University Of Michigan |
ASH1L inhibitors and methods of treatment therewith
|
|
US11118233B2
(en)
|
2016-05-18 |
2021-09-14 |
The University Of Chicago |
BTK mutation and ibrutinib resistance
|
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
CA3035081A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
|
CN110036010A
(zh)
|
2016-09-29 |
2019-07-19 |
亚瑞克西斯制药公司 |
Kras g12c突变蛋白的抑制剂
|
|
WO2018068017A1
(en)
|
2016-10-07 |
2018-04-12 |
Araxes Pharma Llc |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
|
CN110234659A
(zh)
|
2016-12-19 |
2019-09-13 |
特雷罗药物股份有限公司 |
用于敏感性分析的分析肽和方法
|
|
KR20250152110A
(ko)
|
2016-12-22 |
2025-10-22 |
암젠 인크 |
폐암, 췌장암 또는 대장암을 치료하기 위한 kras g12c 억제제로서의 벤즈이소티아졸, 이소티아졸로[3,4-b]피리딘, 퀴나졸린, 프탈라진, 피리도[2,3-d]피리다진 및 피리도[2,3-d]피리미딘 유도체
|
|
EP3573964A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Benzothiophen- und benzothiazolverbindungen und verfahren zur verwendung davon
|
|
EP3573970A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(6-(3-hydroxynaphthalin-1-yl)chinazolin-2-yl)azetidin-1-yl)prop-2-en-1-on-derivate und ähnliche verbindungen wie kras g12c-inhibitoren zur behandlung von krebs
|
|
JP2020505395A
(ja)
|
2017-01-26 |
2020-02-20 |
アラクセス ファーマ エルエルシー |
縮合ｎ−複素環式化合物およびその使用方法
|
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
US11059819B2
(en)
|
2017-01-26 |
2021-07-13 |
Janssen Biotech, Inc. |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
|
US11267885B2
(en)
|
2017-01-26 |
2022-03-08 |
Zlip Holding Limited |
CD47 antigen binding unit and uses thereof
|
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
|
CN110691779B
(zh)
|
2017-03-24 |
2023-10-10 |
库拉肿瘤学公司 |
治疗血液系统恶性肿瘤和尤因肉瘤的方法
|
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
|
CN110869357A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
化合物及其用于治疗癌症的使用方法
|
|
MX2019013954A
(es)
|
2017-05-25 |
2020-08-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras.
|
|
JP2020521740A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体
|
|
US11542248B2
(en)
|
2017-06-08 |
2023-01-03 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
|
US20200207859A1
(en)
|
2017-07-26 |
2020-07-02 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
|
EP3679040B1
(de)
|
2017-09-08 |
2022-08-03 |
Amgen Inc. |
Inhibitoren von kras g12c und verfahren zur verwendung davon
|
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
|
BR112020005212A2
(pt)
|
2017-09-18 |
2020-09-15 |
Sutro Biopharma, Inc. |
conjugado de anticorpo, kit, composição farmacêutica, e, métodos de tratamento ou prevenção e de diagnóstico de uma doença ou condição.
|
|
WO2019060365A1
(en)
|
2017-09-20 |
2019-03-28 |
Kura Oncology, Inc. |
SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
|
|
WO2019075367A1
(en)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
|
|
JP2021502388A
(ja)
|
2017-11-10 |
2021-01-28 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法
|
|
AU2018378935B2
(en)
|
2017-12-07 |
2024-10-31 |
The Regents Of The University Of Michigan |
NSD family inhibitors and methods of treatment therewith
|
|
MX2020010437A
(es)
|
2018-04-05 |
2021-01-29 |
Sumitomo Pharma Oncology Inc |
Inhibidores de axl cinasa y uso de los mismos.
|
|
CA3099118A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
US11090304B2
(en)
|
2018-05-04 |
2021-08-17 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
EP3790886B1
(de)
|
2018-05-10 |
2024-06-26 |
Amgen Inc. |
Kras g12c-inhibitoren zur behandlung von krebs
|
|
ES2938987T3
(es)
|
2018-06-01 |
2023-04-18 |
Amgen Inc |
Inhibidores de KRAS G12c y métodos de uso de los mismos
|
|
WO2019236957A1
(en)
|
2018-06-07 |
2019-12-12 |
The Regents Of The University Of Michigan |
Prc1 inhibitors and methods of treatment therewith
|
|
EP3802537A1
(de)
|
2018-06-11 |
2021-04-14 |
Amgen Inc. |
Kras-g12c-inhibitoren zur behandlung von krebs
|
|
EP3807276B1
(de)
|
2018-06-12 |
2025-12-10 |
Amgen Inc. |
Einen piperazinring umfassende kras g12c-inhibitoren und ihre verwendung zur krebsbehandlung
|
|
KR20210038906A
(ko)
|
2018-07-26 |
2021-04-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
|
|
KR20210045998A
(ko)
|
2018-08-01 |
2021-04-27 |
아락세스 파마 엘엘씨 |
헤테로사이클릭 스피로 화합물 및 암 치료를 위한 그의 사용 방법
|
|
US20220047716A1
(en)
|
2018-09-17 |
2022-02-17 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
|
CN113207291A
(zh)
|
2018-10-24 |
2021-08-03 |
亚瑞克西斯制药公司 |
2-(2-丙烯酰基-2,6-二氮杂螺[3.4]辛-6-基)-6-(1h-吲唑-4-基)苄腈衍生物及相关化合物作为用于抑制肿瘤转移的g12c突变kras蛋白的抑制剂
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
WO2020106640A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
AU2019388998A1
(en)
|
2018-11-29 |
2021-06-03 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|
|
EP3890749B1
(de)
|
2018-12-04 |
2025-10-29 |
Sumitomo Pharma America, Inc. |
Cdk9-inhibitoren und polymorphe davon zur verwendung als mittel zur behandlung von krebs
|
|
CA3123227A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
|
US12459932B2
(en)
|
2018-12-20 |
2025-11-04 |
Amgen Inc. |
KIF18A inhibitors
|
|
AU2019401495B2
(en)
|
2018-12-20 |
2025-06-26 |
Amgen Inc. |
Heteroaryl amides useful as KIF18A inhibitors
|
|
EP3897852A1
(de)
|
2018-12-20 |
2021-10-27 |
Amgen Inc. |
Kif18a-inhibitoren
|
|
AU2020221247B2
(en)
|
2019-02-12 |
2024-12-12 |
Sumitomo Pharma America, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
WO2020180768A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
|
US20230096028A1
(en)
|
2019-03-01 |
2023-03-30 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
|
CA3133460A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
|
WO2020227105A1
(en)
|
2019-05-03 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
|
EP3738593A1
(de)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
|
|
PH12021552922A1
(en)
|
2019-05-21 |
2022-04-04 |
Amgen Inc |
Solid state forms
|
|
KR20220028075A
(ko)
|
2019-07-03 |
2022-03-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
|
|
JP7756070B2
(ja)
|
2019-08-02 |
2025-10-17 |
アムジエン・インコーポレーテツド |
Ｋｉｆ１８ａ阻害剤としてのピリジン誘導体
|
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
|
WO2021026098A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
AU2020324963A1
(en)
|
2019-08-02 |
2022-02-24 |
Amgen Inc. |
KIF18A inhibitors
|
|
US20220402916A1
(en)
|
2019-09-18 |
2022-12-22 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
WO2021067215A1
(en)
|
2019-09-30 |
2021-04-08 |
Agios Pharmaceuticals, Inc. |
Piperidine compounds as menin inhibitors
|
|
JP7634003B2
(ja)
|
2019-10-24 |
2025-02-20 |
アムジエン・インコーポレーテツド |
がんの治療におけるｋｒａｓ ｇ１２ｃ及びｋｒａｓ ｇ１２ｄ阻害剤として有用なピリドピリミジン誘導体
|
|
MX2022005053A
(es)
|
2019-10-28 |
2022-05-18 |
Merck Sharp & Dohme Llc |
Inhibidores de peque?as moleculas de mutante g12c de kras.
|
|
EP4051266A1
(de)
|
2019-10-31 |
2022-09-07 |
Taiho Pharmaceutical Co., Ltd. |
2-aminobut-2-enamidderivate und salze davon
|
|
TW202132315A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras 抑制劑
|
|
CN115873067A
(zh)
|
2019-11-04 |
2023-03-31 |
锐新医药公司 |
Ras抑制剂
|
|
AU2020379734B2
(en)
|
2019-11-04 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
MX2022005525A
(es)
|
2019-11-08 |
2022-06-08 |
Revolution Medicines Inc |
Compuestos de heteroarilo bicíclicos y usos de estos.
|
|
BR112022009390A2
(pt)
|
2019-11-14 |
2022-08-09 |
Amgen Inc |
Síntese melhorada de composto inibidor de kras g12c
|
|
US12473281B2
(en)
|
2019-11-14 |
2025-11-18 |
Amgen Inc. |
Synthesis of KRAS G12C inhibitor compound
|
|
EP4065231A1
(de)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Kovalente ras-inhibitoren und verwendungen davon
|
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
|
CA3163703A1
(en)
|
2020-01-07 |
2021-07-15 |
Steve Kelsey |
Shp2 inhibitor dosing and methods of treating cancer
|
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
|
TW202204333A
(zh)
|
2020-04-08 |
2022-02-01 |
美商阿吉歐斯製藥公司 |
Menin抑制劑及治療癌症之使用方法
|
|
TW202204334A
(zh)
|
2020-04-08 |
2022-02-01 |
美商阿吉歐斯製藥公司 |
Menin抑制劑及治療癌症之使用方法
|
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
WO2021215545A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
|
CN115916194A
(zh)
|
2020-06-18 |
2023-04-04 |
锐新医药公司 |
用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
|
|
EP4178571A4
(de)
|
2020-07-10 |
2024-07-17 |
The Regents Of The University Of Michigan |
Gas41-inhibitoren und verfahren zu ihrer verwendung
|
|
EP4183395A4
(de)
|
2020-07-15 |
2024-07-24 |
Taiho Pharmaceutical Co., Ltd. |
Pyrimidinverbindung enthaltende kombination zur verwendung bei der tumorbehandlung
|
|
US20250195521A1
(en)
|
2020-09-03 |
2025-06-19 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
CN117683049A
(zh)
|
2020-09-15 |
2024-03-12 |
锐新医药公司 |
作为ras抑制剂以治疗癌症的吲哚衍生物
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
WO2022140427A1
(en)
|
2020-12-22 |
2022-06-30 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
|
CA3213079A1
(en)
|
2021-04-13 |
2022-10-20 |
Kristin Lynne ANDREWS |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
|
EP4329818A1
(de)
|
2021-04-30 |
2024-03-06 |
Celgene Corporation |
Kombinationstherapien mit einem anti-bcma-antikörper-wirkstoffkonjugat (adc) in kombination mit einem gammasekretasehemmer (gsi)
|
|
US20230106174A1
(en)
|
2021-05-05 |
2023-04-06 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
EP4334325A1
(de)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Ras-hemmer zur behandlung von krebs
|
|
EP4347041A1
(de)
|
2021-05-28 |
2024-04-10 |
Taiho Pharmaceutical Co., Ltd. |
Kleinmolekülige inhibitoren von kras-mutierten proteinen
|
|
WO2023056589A1
(en)
|
2021-10-08 |
2023-04-13 |
Servier Pharmaceuticals Llc |
Menin inhibitors and methods of use for treating cancer
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
EP4227307A1
(de)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazinverbindungen als shp2-inhibitoren
|
|
TW202346267A
(zh)
|
2022-03-07 |
2023-12-01 |
美商安進公司 |
用於製備４－甲基－２－丙－２－基－吡啶－３－甲腈之方法
|
|
EP4489755A1
(de)
|
2022-03-08 |
2025-01-15 |
Revolution Medicines, Inc. |
Verfahren zur behandlung von immunrefraktärem lungenkrebs
|
|
WO2023211812A1
(en)
|
2022-04-25 |
2023-11-02 |
Nested Therapeutics, Inc. |
Heterocyclic derivatives as mitogen-activated protein kinase (mek) inhibitors
|
|
AU2023285116A1
(en)
|
2022-06-10 |
2024-12-19 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
KR20250043602A
(ko)
|
2022-06-30 |
2025-03-28 |
서트로 바이오파마, 인크. |
항-ror1 항체 및 항체 접합체, 항-ror1 항체 또는 항체 접합체를 포함하는 조성물, 및 항-ror1 항체 및 항체 접합체의 제조 및 사용 방법
|
|
AR129187A1
(es)
|
2022-07-08 |
2024-07-24 |
Nested Therapeutics Inc |
Inhibidores de proteína quinasas activadas por mitógeno (mek)
|
|
AU2023358792A1
(en)
|
2022-10-14 |
2025-04-17 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
|
KR20250164828A
(ko)
|
2023-03-30 |
2025-11-25 |
레볼루션 메디슨즈, 인크. |
Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
|
|
WO2024211663A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
AU2024243852A1
(en)
|
2023-04-07 |
2025-11-06 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
TW202448897A
(zh)
|
2023-04-14 |
2024-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
|
|
AU2024262795A1
(en)
|
2023-04-24 |
2025-11-13 |
Nested Therapeutics, Inc. |
Heterocyclic derivative as mitogen-activated protein kinase (mek) inhibitor
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
TW202515582A
(zh)
|
2023-08-24 |
2025-04-16 |
日商大塚製藥股份有限公司 |
西區嘧啶(cedazuridine)之固定劑量組合
|
|
WO2025080946A2
(en)
|
2023-10-12 |
2025-04-17 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025081117A2
(en)
|
2023-10-13 |
2025-04-17 |
Sutro Biopharma, Inc. |
Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
|
|
TW202535891A
(zh)
|
2023-10-20 |
2025-09-16 |
美商默沙東有限責任公司 |
Ｋｒａｓ蛋白之小分子抑制劑
|
|
WO2025090905A1
(en)
|
2023-10-26 |
2025-05-01 |
Nested Therapeutics, Inc. |
Crystalline forms of 3-[[3-fluoro-2-(methylsulfamoylamino)-4-pyridyl]methyl]-7-[(3-fluoro-2-pyridyl)oxy]-4-methyl-chromen-2-one
|
|
WO2025137507A1
(en)
|
2023-12-22 |
2025-06-26 |
Regor Pharmaceuticals, Inc. |
Sos1 inhibitors and uses thereof
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025250825A1
(en)
|
2024-05-30 |
2025-12-04 |
Sutro Biopharma, Inc. |
Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025259841A1
(en)
|
2024-06-13 |
2025-12-18 |
Nested Therapeutics, Inc. |
Crystalline forms of 3-[[3-fluoro-2-(methylsulfamoylamino)-4-pyridyl]jmethyl]-7-[(3-fluoro-2-pyridyl)oxy]-4-methyl-chromen-2-one
|